Interpretation of NCCN clinical practice guideline for breast cancer in 2018

doi:10.3877/cma.j.issn.1674-0807.2018.03.001

Abstract

Abstract:

The National Comprehensive Cancer Network (NCCN) launched the NCCN Clinical Practice Guideline for Breast Cancer (version 1) on March 20, 2018. This guideline reviews the latest research progress and treatment concepts in the field of breast cancer. On the basis of the previous versions, they update the guidelines for the diagnosis and treatment of breast cancer, which can assist physicians in their clinical practices. This paper interpreted the important changes in the latest version, and discussed its practicability and feasibility in China based on clinical practice, including the TNM staging of breast cancer by American Joint Committee on Cancer (AJCC) (the eighth edition), the principles of breast conserving surgery and pathological evaluation, the recent progress of sentinel lymph node biopsy and new strategy for systematic treatment.

Key words: Breast neoplasms, Diagnosis, Therapeutics, Guideline

Junjie Li, Zhimin Shao. Interpretation of NCCN clinical practice guideline for breast cancer in 2018[J]. Chinese Journal of Breast Disease(Electronic Edition), 2018, 12(03): 129-134.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhrxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0807.2018.03.001

https://zhrxbzz.cma-cmc.com.cn/EN/Y2018/V12/I03/129

References 21

[1]	National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: breast cancer. version 1.2018 [EB/OL]．[2018-04-03]． URL
[2]	中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2017版)[J]. 中国癌症杂志，2017，27(9)：695-759.
[3]	Moran MS, Schnitt SJ, Giuliano AE, et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages Ⅰ and Ⅱ invasive breast cancer [J]. J Clin Oncol, 2014, 32(14): 1507-1515.
[4]	Morrow M, Van Zee KJ, Solin LJ, et al. Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ [J]．Ann Surg Oncol, 2016, 23(12): 3801-3810.
[5]	Galimberti V, Cole BF, Zurrida S, et al International Breast Cancer Study Group trial 23-01 investigators. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial[J]. Lancet Oncol, 2013, 14(4): 297-305.
[6]	Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: The ACOSOG Z0011 (Alliance) randomized clinical trial[J]. JAMA, 2017, 318(10): 918-926.
[7]	Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial[J]．Lancet Oncol, 2014, 15(12): 1303-1310.
[8]	Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from national surgical adjuvant breast and bowel project B-18[J]. J Clin Oncol, 1997, 15(7): 2483-2493.
[9]	Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27[J]. J Clin Oncol, 2003, 21(22): 4165-4174.
[10]	Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study[J]. Lancet Oncol, 2013, 14(7): 609-618.
[11]	Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: The SN FNAC study[J]. J Clin Oncol, 2015, 33(3): 258-264.
[12]	Boughey JC, Suman VJ, Mittendorf EA, et al. Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance) [J]. Ann Surg, 2015, 261 (3): 547-552.
[13]	Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31 [J]. J Clin Oncol, 2011, 29(25): 3366-3373.
[14]	Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer [J]．N Engl J Med, 2011, 365(14): 1273-1283.
[15]	von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer [J]．N Engl J Med, 2017, 377(2): 122-131.
[16]	Martin M, Holmes FA, Ejlertsen B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial [J]．Lancet Oncol, 2017, 18(12): 1688-1700.
[17]	Tolaney SM, Barry WT, Dang CT et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer [J]. N Engl J Med, 2015, 372(2): 134-141.
[18]	Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer [J]．N Engl J Med, 2016, 375(20): 1925-1936.
[19]	Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer [J]．N Engl J Med, 2016, 375(18): 1738-1748.
[20]	Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer[J]. J Clin Oncol, 2017, 35(32): 3638-3646.
[21]	Robertson JFR, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial [J]. Lancet, 2016, 388(10063): 2997-3005.

Please choose a citation manager

Content to export